First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric adenocarcinoma. However, there is no comprehensive study on which platinum-based treatment should be preferred. This s...

Descripción completa

Detalles Bibliográficos
Autores principales: Esen, Selin Aktürk, Ergun, Yakup, Erol, Cihan, Arikan, Rukiye, Er, Muhammed Muhiddin, Atci, Muhammed Mustafa, Topçu, Atakan, Uçar, Gökhan, Akagündüz, Baran, Aykan, Musa Bariş, Özen, Miraç, Baytemur, Naziyet Köse, Özçelik, Melike, Şahin, Elif, Güven, Denizcan, Menekşe, Serkan, Ak, Naziye, Teker, Fatih, Kut, Engin, Şakalar, Teoman, Alan, Özkan, Kaçan, Turgut, Turhal, Nazim Serdar, Kiliçkap, Saadettin, Türker, Sema, Şendur, Mehmet Ali Nahit, Köstek, Osman, Karaağaç, Mustafa, Sakin, Abdullah, Türk, Haci Mehmet, Çağlayan, Dilek, Cihan, Şener, Açikgöz, Yusuf, Uncu, Doğan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519153/
https://www.ncbi.nlm.nih.gov/pubmed/35460397
http://dx.doi.org/10.17305/bjbms.2021.7069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519153/
https://www.ncbi.nlm.nih.gov/pubmed/35460397
http://dx.doi.org/10.17305/bjbms.2021.7069

Ejemplares similares